Rare Disease Clinical Trial Experience

Recruiting from small populations, deriving valid conclusions from limited data, helping sponsors attain orphan drug status – it’s nothing rare for us.

prcom_Asset 1ARROW


Reviewing the new FDA rare disease guidance

In 2019, the U.S. Food and Drug Administration updated its 2015 draft guidelines for drug discovery in rare diseases. The changes can help sponsors like you perform more efficient development programs and gain new insights on the development process.


What to know before your pre-IND meeting

Careful planning is important for all drug development programs, but particularly rare diseases. Pre-IND meetings with the FDA give sponsors the opportunity to discuss their development challenges and determine where regulatory flexibility can be justified.

Helping move rare disease research forward

Deep connections and personal relationships

Researching rare disease requires comfort with the unknown, something we’ve developed over years of studying some of the rarest conditions. Our work spans all aspects of clinical trials and drug development, encompassing more than 242 rare disease studies across multiple indications in the past five years.

Why choose Premier?
  • Deep connections with advocacy groups help us locate hard-to-find patients and engage them as people, not subjects
  • Rare disease expertise ensures that trials stay on course, even when we’re navigating uncharted territory
  • Continuous investment in our capabilities to analyze data, rapidly evolve protocols, and drive clinical trials toward achieving treatment breakthroughs

Featured Resources



mHealth and Remote Clinical Trial Strategies to Include in Your next Study

Premier Insight

Premier Insight

Site Selection, Manufacturing, & Long-Term Follow-Up in a Transition Phase 1/2 Gene Therapy Trial

White Paper

White Paper

Mapping the New Landscape of Orphan Drug Development

Premier Thought Leadership

Angi Robinson

Angi Robinson has been conducting pediatric and rare disease studies at Premier Research for more than 14 years. She has provided oversight and full management support for over 30 rare disease studies, including multiple U.S. and global programs. She has also supported FDA pre-IND meetings, IND submissions, and NDA/BLA project directorship.

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.